Osteogenesis imperfecta: an update on clinical features and therapies
- PMID: 32621590
- PMCID: PMC7694877
- DOI: 10.1530/EJE-20-0299
Osteogenesis imperfecta: an update on clinical features and therapies
Abstract
Osteogenesis imperfecta (OI) is an inherited skeletal dysplasia characterized by bone fragility and skeletal deformities. While the majority of cases are associated with pathogenic variants in COL1A1 and COL1A2, the genes encoding type I collagen, up to 25% of cases are associated with other genes that function within the collagen biosynthesis pathway or are involved in osteoblast differentiation and bone mineralization. Clinically, OI is heterogeneous in features and variable in severity. In addition to the skeletal findings, it can affect multiple systems including dental and craniofacial abnormalities, muscle weakness, hearing loss, respiratory and cardiovascular complications. A multi-disciplinary approach to care is recommended to address not only the fractures, reduced mobility, growth and bone pain but also other extra-skeletal manifestations. While bisphosphonates remain the mainstay of treatment in OI, new strategies are being explored, such as sclerostin inhibitory antibodies and TGF beta inhibition, to address not only the low bone mineral density but also the inherent bone fragility. Studies in animal models have expanded the understanding of pathomechanisms of OI and, along with ongoing clinical trials, will allow to develop better therapeutic approaches for these patients.
Conflict of interest statement
Declaration of interest
The authors declare no conflicts of interest.
Figures
Similar articles
-
Osteogenesis imperfecta.Nat Rev Dis Primers. 2017 Aug 18;3:17052. doi: 10.1038/nrdp.2017.52. Nat Rev Dis Primers. 2017. PMID: 28820180 Review.
-
Osteogenesis imperfecta - A clinical update.Metabolism. 2018 Mar;80:27-37. doi: 10.1016/j.metabol.2017.06.001. Epub 2017 Jun 8. Metabolism. 2018. PMID: 28625337 Review.
-
Osteogenesis imperfecta: diagnosis and treatment.Curr Osteoporos Rep. 2014 Sep;12(3):279-88. doi: 10.1007/s11914-014-0225-0. Curr Osteoporos Rep. 2014. PMID: 24964776 Review.
-
Pharmacological and biological therapeutic strategies for osteogenesis imperfecta.Am J Med Genet C Semin Med Genet. 2016 Dec;172(4):367-383. doi: 10.1002/ajmg.c.31532. Epub 2016 Nov 3. Am J Med Genet C Semin Med Genet. 2016. PMID: 27813341 Review.
-
Update on the evaluation and treatment of osteogenesis imperfecta.Pediatr Clin North Am. 2014 Dec;61(6):1243-57. doi: 10.1016/j.pcl.2014.08.010. Epub 2014 Sep 22. Pediatr Clin North Am. 2014. PMID: 25439022 Review.
Cited by
-
Genetic Background of Medication-Related Osteonecrosis of the Jaw: Current Evidence and Future Perspectives.Int J Mol Sci. 2024 Sep 29;25(19):10488. doi: 10.3390/ijms251910488. Int J Mol Sci. 2024. PMID: 39408816 Free PMC article. Review.
-
Respiratory insufficiency in an infant with osteogenesis imperfecta.Respir Med Case Rep. 2024 Sep 17;52:102107. doi: 10.1016/j.rmcr.2024.102107. eCollection 2024. Respir Med Case Rep. 2024. PMID: 39350960 Free PMC article.
-
Evaluation of functioning and associated factors in children and adolescents with osteogenesis imperfecta.Rev Paul Pediatr. 2024 Sep 9;43:e2023193. doi: 10.1590/1984-0462/2025/43/2023193. eCollection 2024. Rev Paul Pediatr. 2024. PMID: 39258640 Free PMC article.
-
Losartan alters osteoblast differentiation and increases bone mass through inhibition of TGFB signalling in vitro and in an OIM mouse model.Bone Rep. 2024 Jul 25;22:101795. doi: 10.1016/j.bonr.2024.101795. eCollection 2024 Sep. Bone Rep. 2024. PMID: 39185375 Free PMC article.
-
The vitamin D status in a Chinese osteogenesis imperfecta population and its correlation with bone metabolic markers and bone density.Front Nutr. 2024 Aug 5;11:1390668. doi: 10.3389/fnut.2024.1390668. eCollection 2024. Front Nutr. 2024. PMID: 39161912 Free PMC article.
References
-
- Marini JC, Forlino A, Bachinger HP, Bishop NJ, Byers PH, Paepe A, Fassier F, Fratzl-Zelman N, Kozloff KM, Krakow D et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017. Aug 18;3:17052. - PubMed
-
- Mortier GR, Cohn DH, Cormier-Daire V, Hall C, Krakow D, Mundlos S, Nishimura G, Robertson S, Sangiorgi L, Savarirayan R et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am J Med Genet A. 2019. Dec;179(12):2393–419. - PubMed
-
- Semler O, Garbes L, Keupp K, Swan D, Zimmermann K, Becker J, Iden S, Wirth B, Eysel P, Koerber F et al. A mutation in the 5’-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. Am J Hum Genet. 2012. August 10;91(2):349–57. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
